Majority of stockholders support pasithea directors at special meeting

Miami beach, fla., dec. 14, 2022 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (cns) disorders, today announced the final results of the special meeting of stockholders (“special meeting”) held on december 9, 2022.
KTTA Ratings Summary
KTTA Quant Ranking